Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-768-7 | CAS number: 1663-39-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 Aug 2001 - 05 Nov 2001
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2001
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- other: micronucleus assay
Test material
- Reference substance name:
- tert-butyl acrylate
- EC Number:
- 216-768-7
- EC Name:
- tert-butyl acrylate
- Cas Number:
- 1663-39-4
- Molecular formula:
- C7H12O2
- IUPAC Name:
- tert-butyl acrylate
Constituent 1
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): Tert.-Butylacrylat
- Physical state: liquid
- Lot/batch No.: Tank B 601
- Analytical purity: 99.69 % (Stability of the test substance in olive oil was determined analytically.)
- Stability under test conditions: Storage stability of the test substance covering the period of the study was determined by the sponsor by recharacterisation after completion of the experimental phase of the study.
- Storage condition of test material: Refrigerator, protected from light
Test animals
- Species:
- mouse
- Strain:
- NMRI
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: RCC Ltd., Fuellinsdorf, CH
- Age at study initiation: 7-10 weeks
- Weight at study initiation: males 46.7±3.0 g; females 32.2 ± 4.9g
- Assigned to test groups randomly: yes
- Housing: individually
- Diet: standard diet, ad libitum (ALTROMIN 1324, D-32791 Lage/Lippe )
- Water: ad libitum, (Gemeindewerke, D-64380 Rossdorf)
- Acclimation period: minimum 5 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 4
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- - Vehicle(s)/solvent(s) used: olive oil
- Justification for choice of solvent/vehicle: The vehicle was chosen to its relative non-toxicity for the animals - Details on exposure:
- - i.p. injection of 10 mL/kg bw
- Duration of treatment / exposure:
- single treatment
- Frequency of treatment:
- single treatment
- Post exposure period:
- 24 or 48 h
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 other: mg/kg bw
- Remarks:
- males
- Dose / conc.:
- 200 other: mg/kg bw
- Remarks:
- males
- Dose / conc.:
- 400 other: mg/kg bw
- Remarks:
- males
- Dose / conc.:
- 125 other: mg/kg bw
- Remarks:
- females
- Dose / conc.:
- 250 other: mg/kg bw
- Remarks:
- females
- Dose / conc.:
- 500 other: mg/kg bw
- Remarks:
- females
- No. of animals per sex per dose:
- - Pre-tests: 2 + 5 per sex and per dose
- Main-test: 12 per sex in the high dose and 6 per sex in the mid and low dose, each - Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Cyclophosphamide, dissolved in water
- Route of administration: i.p.
- Dose: 40 mg/kg bw
Examinations
- Tissues and cell types examined:
- Bone marrow cells were used. At least 2000 PCEs per animal were scored for micronuclei.
- Details of tissue and slide preparation:
- CRITERIA FOR DOSE SELECTION:
It is generally recommended to use the maximum tolerated dose or the highest dose that can be formulated and administered reproducibly or 2000 mg/kg as the upper limit for non-toxic test substances.
The maximum tolerated dose level is determined to be the dose that causes toxic reactions without having major effects on survival.
The maximum tolerated dose was therefore determined in extensive pre-tests in which doses of 400 to 1000 mg/kg were administered intraperitoneal to male and female mice.
Results of the pre-tests:
In a first pretest male mice (2 animals/dose) were administered i.p. 400, 500 and 1000 mg/kg. Both animals of the 1000 mg/kg dose died, also 1/2 animals of the 500 mg/kg dose. Clinical signs described were reduction of the spontaneous activity, abdominal position eyelid closure and apathy. To confirm the results 5 animals per dose were administered 400 and 500 mg/kg i.p.. Two of the animals in the 500 mg/kg dose died. All animals of both groups showed a reduction of the spontaneous activity and apathy, further clinical signs were abdominal position, and eyelid closure.
Based on this results a clear systemic availability of the test substance was proved in male mice.
Also in female mice the systemic availability and the maximum tolerated dose was determined in pre-tests.
Again in a first pretest 2 mice per dose received 500, 600, 750 and 1000 mg/kg i.p. The animals of the 750 and 1000 mg/kg dose died. Clinical signs in all groups were reduction of the spontaneous activity, apathy and eyelid closure. In confirming prestudies 5 female mice per group were administered i.p. 500 and 600 mg/kg. 4/5 mice in the 600 mg/kg dose died. All animals showed reduction of spontaneous activity, further clinical signs observed were abdominal position, eyelid closure and apathy.
The volume to be administered should be compatible with physiological space available. Three adequate spaced dose levels spaced by a factor of 2 were applied at the central sampling interval 24 h after treatment. For the highest dose level an additional sample was taken at 48 h after treatment.
TREATMENT AND SAMPLING TIMES (in addition to information in specific fields):
Males:
Negative control and 400 mg/kg bw: sampling after 24 and 48 h
Positive control, 100 and 200 mg/kg bw: sampling after 24 h
Females:
Negative control and 500 mg/kg bw: sampling after 24 and 48 h
Positive control, 125 and 250 mg/kg bw: sampling after 24 h
DETAILS OF SLIDE PREPARATION:
The cell suspension was centrifuged at 1500 rpm (390 x g) for 10 minutes and the supernatant was discarded. A small drop of the resuspended cell pellet was spread on a slide. The smear was air-dried and then stained with May-Grünwald (MERCK, D-64293 Darmstadt)/Giemsa (Gurr, BDH Limited Poole, Great Britain). Cover slips were mounted with EUKITT (KINDLER, D-79110 Freiburg). At least one slide was made from each bone marrow sample.
OTHER:
To describe a cytotoxic effect due to the treatment with the test substance the ratio between polychromatic (PCE) and normochromatic erythrocytes (NCE) was determined in the sample and reported as number of NCEs per 2000 PCEs.
After treatment with the test substance the number of NCEs was not substantially changed as compared to the mean value of NCEs of the vehicle control thus indicating that tert-butyl acrylate had no cytotoxic effectiveness in the bone marrow. - Evaluation criteria:
- A test substance is classified as mutagenic if it induces either a dose-related increase in the number of micronucleated polychromatic erythrocytes, which clearly exceeds the negative control range or a relevant positive response for at least one of the test points. Statistical methods (nonparametric Mann-Whitney test) can be used as an aid in evaluating the results. However, the primary point of consideration is the biological relevance of the results.
A test substance producing neither a dose-related increase in the number of micronucleated polychromatic erythrocytes nor a positive response at any of the test points is considered non-mutagenic in this system.
Acceptance Criteria
The study was considered valid as the following criteria were met:
- the negative controls are in the range of the laboratory's historical control data (0.30 - 1.5 per thousand; mean = 0.86 ± 0.27 per thousand PCEs with micronuclei).
- the positive controls are in the range of the laboratory's historical control data (10.0 - 27.1 per thousand; mean = 16.53 ± 4.09 per thousand PCEs with micronuclei).
- at least 80 % of animals are evaluable
- the test was performed up to the maximum tolerated dose, clear signs of systemic toxicity demonstrated systemic availablity of the test material
Results and discussion
Test results
- Key result
- Sex:
- male/female
- Genotoxicity:
- negative
- Toxicity:
- yes
- Remarks:
- at the highest dose level
- Vehicle controls validity:
- valid
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Additional information on results:
- Systemic availablity as well as the maximum tolerated dose were determined in pre-studies. Both was also shown by the clinical effects in the main study, all animals of the highest dose groups showed reduction of the spontaneous activity, eyelid closure, apathy and abdominal position after the application. There was no significant cytotoxic effect on the PCE/NCE ratio in the bone marrow for tBA as well as for the significantly micronuclei inducing positive control.
Any other information on results incl. tables
males
test group dose sampling PCEs with PCE / NCE
mg/kg bw time (h) micronuclei
(percentile)
vehicle 0 24 0.50 2000 / 1821
tBA 100 24 0.60 2000 / 1855
tBA 200 24 0.60 2000 / 1760
tBA 400 24 0.70 2000 / 1878
positiv
control 40 24 19.80 2000 / 1719
vehicle 0 48 0.10 2000 / 1886
tBA 400 48 0.20 2000 / 1886
females
test group dose sampling PCEs with PCE / NCE
mg/kg bw time (h) micronuclei
(percentile)
vehicle 0 24 0.70 2000 / 1509
tBA 125 24 0.10 2000 / 1542
tBA 250 24 0.90 2000 / 1714
tBA 500 24 0.20 2000 / 1573
positiv
control 40 24 13.70 2000 / 1627
vehicle 0 48 0.20 2000 / 1752
tBA 500 48 0.40 2000 / 1674
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
